FOLD Amicus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FOLD

Price (delayed)

$10.54

Market cap

$3.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$3.31B

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics ...

Highlights
The EPS has grown by 38% YoY and by 14% from the previous quarter
The net income rose by 36% YoY and by 13% QoQ
Amicus Therapeutics's quick ratio has decreased by 14% YoY but it has increased by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.amicusrx.com
Peers: PLX BIIB BMRN ESPR

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
295.38M
Market cap
$3.11B
Enterprise value
$3.31B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
19.3
Price to sales (P/S)
7.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.29
Earnings
Revenue
$399.36M
EBIT
-$99.95M
EBITDA
-$92.08M
Free cash flow
-$76.53M
Per share
EPS
-$0.51
Free cash flow per share
-$0.26
Book value per share
$0.55
Revenue per share
$1.35
TBVPS
$1.9
Balance sheet
Total assets
$777.88M
Total liabilities
$617.71M
Debt
$445.06M
Equity
$160.17M
Working capital
$315.37M
Liquidity
Debt to equity
2.78
Current ratio
2.88
Quick ratio
2.23
Net debt/EBITDA
-2.15
Margins
EBITDA margin
-23.1%
Gross margin
90.7%
Net margin
-38%
Operating margin
-18.7%
Efficiency
Return on assets
-20.4%
Return on equity
-119.5%
Return on invested capital
-16.8%
Return on capital employed
-16.4%
Return on sales
-25%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
-1.59%
1 week
-0.09%
1 month
-8.59%
1 year
-8.27%
YTD
-25.72%
QTD
-10.53%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$399.36M
Gross profit
$362.03M
Operating income
-$74.63M
Net income
-$151.58M
Gross margin
90.7%
Net margin
-38%
The operating margin has soared by 71% YoY and by 38% QoQ
Amicus Therapeutics's operating income has surged by 65% YoY and by 33% QoQ
FOLD's net margin is up by 47% year-on-year and by 18% since the previous quarter
The net income rose by 36% YoY and by 13% QoQ

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
19.3
P/S
7.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.29
The EPS has grown by 38% YoY and by 14% from the previous quarter
The P/B is 33% below the last 4 quarters average of 28.7 but 24% above the 5-year quarterly average of 15.6
The equity has grown by 30% YoY and by 20% from the previous quarter
FOLD's price to sales (P/S) is 36% lower than its 5-year quarterly average of 12.2 and 23% lower than its last 4 quarters average of 10.1
FOLD's revenue is up by 21% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Amicus Therapeutics business performance
The ROS has soared by 60% YoY and by 34% from the previous quarter
The ROIC has grown by 47% YoY and by 26% from the previous quarter
FOLD's ROA is up by 33% YoY and by 14% from the previous quarter
Amicus Therapeutics's return on equity has increased by 19% QoQ and by 16% YoY

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 26% greater than its total liabilities
Amicus Therapeutics's quick ratio has decreased by 14% YoY but it has increased by 7% from the previous quarter
FOLD's total assets is up by 7% year-on-year
FOLD's debt is 178% greater than its equity
The equity has grown by 30% YoY and by 20% from the previous quarter
FOLD's debt to equity is down by 24% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.